Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases

Front Med (Lausanne). 2022 Sep 21:9:1020859. doi: 10.3389/fmed.2022.1020859. eCollection 2022.

Md Yuzaiful Md Yusof^{1

2}, Stefano Alivernini^{3

4}, Katerina Chatzidionysiou⁵

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
² National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, United Kingdom.
³ Immunology Core Facility, Gemelli Science Technological Park, GSTeP, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
⁴ Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome, Italy.
⁵ Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

No abstract available

Keywords: B lymphocyte; Sjögren's syndrome; biological DMARDs; rheumatoid arthritis; systemic lupus erythematosus.

Publication types